ation in the blood may be necessary to assess complications, such as acute hyperglycemia or hypoglycemia due to GI treatment, prior to clinical 14 / 18 HIF-1 Inhibition plus GI Treatment for Gastric Cancer Fig 7. The anti-tumor effect of GI treatment on HIF-1 knockdown KD cells under hypoxic conditions. HIF-1 plays a central role in controlling the ROS level in the SC cells under hypoxia. HIF-1 induces the gene expression of ten specific genes under hypoxia. The apoptotic effect induced by HIF-1 knockdown plus GI treatment in the KD cells under hypoxia. The hypoxia-induced expression of the 10 genes is reduced by HIF-1 knockdown. NC: Nucleus, MC: Mitochondria, GL: Glycolysis, WE: Warburg effect, MP: Mitophagy, IR: Insulin receptor. doi:10.1371/journal.pone.0137257.g007 application. Based on the findings of the present study, a possible mechanism for the antitumor effect of GI treatment in KD cells under hypoxia is shown in Fig 7. In the future, instead of HIF-1 knockdown, HIF-1 inhibiting drugs may enable this combined therapy to be clinically feasible. Although small-molecule inhibitors of HIF-1 have been developed, none of these have been clinically approved due to the lack of objective effects and the high toxicity. In the present study, KD-PBS still exhibited tumor growth, although higher apoptosis was observed in comparison to the SC tumors. Treatment with a HIF-1 inhibitor alone may not be sufficient to inhibit the tumor growth. In conclusion, HIF-1 inhibition combined with GI treatment may be a promising target for the hypoxic region in gastric cancer, where conventional chemotherapy often fails. 15 / 18 HIF-1 Inhibition plus GI Treatment for Gastric Cancer Neoplastic endothelial proliferative diseases such as human angiosarcoma and PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19734939 canine hemangiosarcoma are serious diseases for both humans and dogs. AS usually occurs in the skin, especially the scalp and face of elderly people, as well as in the female breast, which sarcomas arising at this site are usually Piclidenoson resulted from radiation therapy. Other primary sites are also reported to be the liver and spleen; however, the incidence in those sites are 
less frequent than that of dermal AS. The prognosis of AS is poor because of the frequent local recurrence and distant metastasis. The overall 5-year survival rate is approximately 43 to 60% with the median survival being 7 months. However, AS has not been well studied compared to the other major tumors because of its low incidence; i.e., it accounts for only 1.8% of soft-tissue sarcomas. The lack of case number and research modality for AS makes it difficult to understand the detailed pathobiology of AS and to develop a new strategy for the treatment despite the poor prognosis. HSA, a canine malignant endothelial neoplasm, shares many features with AS in terms of malignant behaviors such as the low survival rate and frequent metastasis. Surgery and doxorubicin-based chemotherapy increase survival duration; however, the 1-year survival rate is less than 10%. Unlike in the case of AS, HSA is relatively common, accounting for approximately 20% of all canine soft-tissue sarcomas. Although the most PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/19734877 common primary site of HSA is the spleen, HSA occurs in various organs such as liver, right atrium of heart and skin with much higher incidence than that in humans. Domestic dogs share environmental factors with humans and develop HSA spontaneously with high incidence. Furthermore, the clinical and pathologic similarities between AS and HSA make